Clinical studies and experimental evidence indicate that the activation of PXR by specific agonists, such as vitamin K2 and others, can influence the progression of hepatocellular and colorectal cancer [87,97,98,99,100,101,102]. This evidence concerns the gene NR1I2 and colorectal cancer.